- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01568788
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
Post-marketing Clinical Observation of Hualan's Inactivated Influenza Vaccine: A Single Center, Parallelled, Controlled, Randomised Clinical Trial
Phase III clinical trial was carried out in Jintan city, Jiangsu Province, China in May, 2006. Trial results showed that the vaccine had proved safety and immunogenicity. Influenza vaccine of Hualanbio has obtained production permission and marketing authorization in May, 2008.
In order to further investigate the safety and immunogenicity of the vaccine in the market, The clinical observation was planned to be conducted in Mianyang city (Yanting County), Sichuan Province, China.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Dosage and administration route in this clinical trial:
Subjects age 3 years or older was vaccinated following a single 0.5ml dose immunization regime.
The preferred site of injection was the at the skin near outboard deltoid muscle of the upper arm.
The administration route is after the sanitization with 75% alcohol, intramuscularly inject the test vaccine or the control vaccines when the skin was slightly dried for those subjects complied with the inclusion requirements.
Safety indicators:
- Post-vaccination local and systemic adverse reaction levels, together with the soliciting adverse reaction within 30 minutes ;
- Post-vaccination local and systemic adverse reaction levels, together with the soliciting adverse reactions through 6 hours to the 29th day ;
- Summarize the adverse events/severe adverse events and the incidence levels from the inclusion of the subjects to the completion of the clinical trial.
Immunogenicity indicators:
Evaluate the Post-vaccination immunogenicity of the test and the control influenza vaccines in persons age 3 years and older by its HI antibody level on Day 28.
Take 1:10 serum dilution as the minimum dilutability. The seroconversion in this trial was defined as the post-vaccination HI antibody titer ≥ 1:40 when the HI antibody < 1:10 before the vaccination or the post-vaccination HI antibody titer quadruply increased when HI antibody ≥ 1:10 before the vaccination.
The Immunogenicity criteria set for this clinical trial is the seroconversion shall be > 40% after 14 days of the vaccination.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Sichuan
-
Mianyang, Sichuan, Kina, 621000
- Yanting County
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy male or female age 3 and older, volunteers or their guardians are able to understand and sign the informed consent;
- Healthy male or female by inquiring illness history, physical examination and clinical judgment and who complies with vaccination of this product;
- Be able to comply with the requirement of clinical trial protocol;
- Have no history of vaccination within the past 6 months and vaccination with other product within the latest 1 week;
- Axillary temperature <37.1℃.
Exclusion Criteria:
- Subject that was allergic to eggs and any component of the vaccine, or has history of other allergy;
- Fever, acute disease or acute onset of chronic disease and influenza;
- Guillain-Barre Syndrome
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Inactivated Influenza Vaccine
15μg HA/strain/0.5ml/syringe,
Hualan Biologicals
|
200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe,
one dose regime
Andre navn:
|
|
Aktiv komparator: Inactivated Influenza Vaccine of Pasteur
15ug HA/strain/0.5ml/syringe,
Sanofi Pasteur
|
200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
Andre navn:
|
|
Aktiv komparator: Inactivated Influenza Vaccine of GSK
15ug HA/strain/0.5ml/syringe,
GSK
|
200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe,
one dose regime
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall forsøkspersoner med bivirkninger som et mål på sikkerhetsstudie
Tidsramme: 28 dager etter vaksinasjonen
|
Lokale reaksjoner, systemiske reaksjoner, alvorlighetsgrad og AEFI-korrelasjon
|
28 dager etter vaksinasjonen
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Observation of the immunological effect
Tidsramme: 28 days after the immunization
|
HI antibody seroconversion ratios
|
28 days after the immunization
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Pei-ru Zhang, Immune Planning Institute of Mianyang Center for Disease Prevention and Control
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Hualanbio-influenza-IV-002
- Hualanbio-003 (Annet stipend/finansieringsnummer: Hualan Biological Engineering INC.)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .